KTRA has 36-month beta value of 0.55. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for KTRA is 38.96M, and currently, short sellers hold a 5.64% ratio of that float. The average trading volume of KTRA on April 01, 2024 was 13.21M shares.
KTRA) stock’s latest price update
Kintara Therapeutics Inc (NASDAQ: KTRA)’s stock price has increased by 16.20 compared to its previous closing price of 0.09. However, the company has seen a 13.66% increase in its stock price over the last five trading sessions. PennyStocks reported 2024-03-31 that Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.
KTRA’s Market Performance
Kintara Therapeutics Inc (KTRA) has experienced a 13.66% rise in stock performance for the past week, with a 2.67% rise in the past month, and a -42.22% drop in the past quarter. The volatility ratio for the week is 6.10%, and the volatility levels for the past 30 days are at 9.79% for KTRA. The simple moving average for the last 20 days is 9.97% for KTRA stock, with a simple moving average of -94.98% for the last 200 days.
KTRA Trading at -4.47% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.26% of loss for the given period.
Volatility was left at 9.79%, however, over the last 30 days, the volatility rate increased by 6.10%, as shares sank -2.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.18% lower at present.
During the last 5 trading sessions, KTRA rose by +13.66%, which changed the moving average for the period of 200-days by -96.94% in comparison to the 20-day moving average, which settled at $0.0944. In addition, Kintara Therapeutics Inc saw -38.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTRA
The total capital return value is set at -720.4. Equity return is now at value -329.00, with -179.36 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To put it simply, Kintara Therapeutics Inc (KTRA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
